A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study is a one-arm, open, multicenter phase 1b/2 clinical trial of YL-13027 combined
with Sintilimab in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D
and observing the preliminary efficacy.The trial can be divided into two parts: dose
escalation part and expansion part.Sintilimab is administered as a fixed-dose intravenous
injection(200mgQ3w）.